Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Boston Therapeutics, Inc. (BTHE) is Creating a Better Drug to Prevent and Treat Diabetes

In the United States alone, an estimated 26 million people have Type 2 diabetes while another 80 million or so people are pre-diabetic. Recognizing that there are urgent, unfulfilled medical needs for both the pre-diabetic and diabetic community, Boston Therapeutics is concentrating on creating better technology to prevent diabetes and its complications.

Considering the varied and dangerous complications that stem from uncontrolled diabetes (such as heart disease, stroke, and kidney damage), Boston Therapeutics’ goal is to better control glucose levels in patients throughout the day using innovations in complex carbohydrate chemistry.

The key diabetic solution in the company’s arsenal is PAZ320, a non-systemic, non-toxic chewable drug candidate that is intended to be taken before meals to reduce the post-meal elevation of blood glucose in patients living with Type 2 diabetes. PAZ320 slows down the enzymes that release glucose from complex carbohydrates in foods during digestion and thereby reduces the amount of glucose absorbed through the intestine.

Boston Therapeutics is developing the PAZ320 drug for potential use with metformin, a popular anti-diabetic drug, and as a better alternative to Acarbose, which has side effects and limited functionality. PAZ320 has already completed a Phase 2 clinical trial to reduce post-meal glucose elevation and the company hopes to take it to Phase 3 trial by the third quarter of 2014.

Alongside PAZ320, Boston Therapeutics has two other products in the pipeline: IPOXYN and OXYFEX.

IPOXYN, a universal oxygen carrier and cell bodyguard, is an injectable drug candidate for the prevention of necrosis, the death of cells in an organ or tissue due to a failure of blood supply. IPOXYN would also be appropriate for the treatment of hypoxia, a deficiency in the amount of oxygen reaching the tissues, as well as other ischemic conditions which may lead to necrosis. IPOXYN oxygen carriers are in the pre-clinical stage of drug development.

OXYFEX, a reproduction of IPOXYN, is Boston Therapeutics’ offering to the veterinary market. OXYFEX is able to serve as an oxygen delivery mechanism for animals suffering from damaged or ischemic tissue due to traumatic and surgical blood loss.

Boston Therapeutics has engaged in designing, producing, and marketing novel compounds and therapeutic drugs that address diabetes and other inflammatory diseases since its start in 2009.

For more information, visit

Let us hear your thoughts below:

This entry was posted in Boston Therapeutics Inc. BTHE. Bookmark the permalink.

Comments are closed.